Subject(s)
Humans , Male , Prostatic Neoplasms/epidemiology , Population Surveillance , Watchful Waiting/methods , Prostatectomy/methods , Prostatic Neoplasms/diagnosis , Prostatic Neoplasms/pathology , Biopsy/methods , Magnetic Resonance Imaging/methods , Risk , Prostate-Specific Antigen , Disease Progression , Ablation Techniques/methodsABSTRACT
ABSTRACT Purpose: Robotic assisted radical prostatectomy (RARP) presents challenges for the surgeon, especially during the initial learning curve. We aimed to evaluate early and mid-term functional outcomes and complications related to vesicourethral anastomosis (VUA), in patients who underwent RARP, during the initial experience in an academic hospital. We also assessed possible predictors of postoperative incontinence and compared these results with the literature. Materials and Methods: We prospectively collected data from consecutive patients that underwent RARP. Patients with at least 6 months of follow-up were included in the analysis for the following outcomes: time to complete VUA, continence and complications related to anastomosis. Nerve-sparing status, age, BMI, EBL, pathological tumor staging, and prostate size were evaluated as possible factors predicting early and midterm continence. Results were compared with current literature. Results: Data from 60 patients was assessed. Mean time to complete VUA was 34 minutes, and console time was 247 minutes. Continence in 6 months was 90%. Incidence of urinary leakage was 3.3%, no patients developed bladder neck contracture or postoperative urinary retention. On multivariate analysis, age and pathological staging was associated to 3-month continence status. Conclusion: Our data show that, during early experience with RARP in a public university hospital, it is possible to achieve good results regarding continence and other outcomes related to VUA. We also found that age and pathological staging was associated to early continence status.
Subject(s)
Humans , Male , Aged , Prostatectomy/methods , Prostatic Neoplasms/surgery , Urethra/surgery , Urinary Bladder/surgery , Robotic Surgical Procedures/methods , Postoperative Complications , Prostatectomy/adverse effects , Anastomosis, Surgical/adverse effects , Anastomosis, Surgical/methods , Prospective Studies , Treatment Outcome , Robotic Surgical Procedures/adverse effects , Hospitals, University , Middle AgedABSTRACT
A ceratopigmentação, ou tatuagem do estroma corneano, é método utilizado para tratar cosmeticamente lesões corneanas como leucoma e coloboma traumático de íris. Pode-se realizar a aplicação do pigmento pela micropunção estromal ou associada à ceratectomia ou ceratoplastia lamelar. Demonstramos um caso de tatuagem estromal corneana associada a ceratoplastia lamelar em paciente com leucoma corneano extenso, com irregularidade de superfície, que não tolerava lentes de contato e sem prognóstico visual. Houve também correção do estrabismo divergente no mesmo tempo cirúrgico. Após um ano de seguimento, o pigmento mantém-se impregnado no estroma corneano, proporcionando bom aspecto estético. Em conclusão, a técnica da tatuagem associada ao transplante lamelar da córnea constitui bom método para tratamento cosmético do leucoma central com irregularidades da superfície corneana.
Stromal cornea tattooing has been used for esthetic treatment of corneal scars as leukoma and iris coloboma. The coloring agent can be applied through stromal micropuncture or associated with lamellar keratectomy or keratoplasty. We report a case of stromal tattooing associated with lamellar keratectomy in a patient's eye that had extensive leukoma and irregular corneal surface. Visual acuity in the operated eye was no light perception and the patient did not tolerate the use of cosmetic contact lens. Correction of divergent strabismus was also performed during the surgery. After one year follow-up, the ink is still impregnated in the corneal stroma, giving a good esthetic aspect. In conclusion, the technique of corneal tattooing associated with lamellar keratectomy is a good method for the cosmetic treatment of central leukoma with corneal irregularity.